DXB announces approval for Phase III COVID-19 trials
Email Sep 27, 2021
On Friday last week, DXB announced that the main drug regulator in India has recommended approval for DXB’s Phase III clinical trials on COVID-19 treatment, specifically for patients with respiratory complications intended for hospitalisation — its CLARITY 2.0 study.
We Participated in the CPH placement - and so did Billionaire John Hancock
Email Mar 26, 2021
Creso Pharma (ASX: CPH) is edging closer to becoming part of our long term portfolio. CPH just raised $18M, which significantly shores up the balance sheet - another tick in the box for us as CPH builds trust to enter our long term portfolio.
CPH to be the First ASX Stock to Acquire 100% of a Psychedelics Company
Article Mar 15, 2021
Creso Pharma (ASX: CPH) will be the first ASX listed stock to acquire 100% of a psychedelics company. CPH is set to acquire Canada based Halucenex Life Sciences Inc., an established psychedelics company developing treatments for a range of mental illnesses.
CPH deliver Financials and Confirms US Cannabis Market Entry
Email Mar 01, 2021
Creso Pharma (ASX: CPH) just released its preliminary financial reports for the year, which as expected show a bunch of impairments, debt clean ups and other scary looking one off costs that come with a balance sheet clean up - these are all out of the way now.
What’s Happening to the CPH Share Price?
Article Dec 02, 2020
Over recent days, Creso Pharma (ASX: CPH) appears to have gained some significant momentum. Momentum includes three new purchase orders for Creso Pharma’s anibidiol® line of animal health products were signed today, to a value of $A$414,000.
Short Term Trade Update: What’s Happening to the CPH Share Price?
Email Dec 02, 2020
We put out a short note on Creso Pharma (ASX: CPH) to some of you that might have previously invested in the stock and not had a positive experience. After a couple of false starts, our plan is to ride this momentum over the coming weeks and hopefully recoup some of our previous losses.
Canopy Growth Founder Joins a Refreshed, Re-Set and Re-Funded CPH
Article Archived Oct 13, 2020
While Creso Pharma (ASX: CPH) continues to sign purchase orders and has appointed Bruce Linton as an advisor, it is a highly speculative investment, and our intent is to hold for the coming months through to Christmas to see how the company’s strategy plays out.